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Abstract
Siglec-15 is a conserved sialic acid-binding Ig-like lectin expressed on osteoclast progenitors,
which plays an important role in osteoclast development and function. It is also expressed by
tumor-associated macrophages and by some tumors, where it is thought to contribute to the
immunosuppressive microenvironment. It was shown previously that engagement of macrophage-
expressed Siglec-15 with tumor cells expressing its ligand, sialyl Tn (sTn), triggered production
of TGF-β. In the present study, we have further investigated the interaction between Siglec-15
and sTn on tumor cells and its functional consequences. Based on binding assays with lung and
breast cancer cell lines and glycan-modified cells, we failed to see evidence for recognition of
sTn by Siglec-15. However, using a microarray of diverse, structurally defined glycans, we show
that Siglec-15 binds with higher avidity to sialylated glycans other than sTn or related antigen
sequences. In addition, we were unable to demonstrate enhanced TGF-β secretion following co-
culture of Siglec-15-expressing monocytic cell lines with tumor cells expressing sTn or following
Siglec-15 cross-linking with monoclonal antibodies. However, we did observe activation of the
SYK/MAPK signaling pathway following antibody cross-linking of Siglec-15 that may modulate the
functional activity of macrophages.
Key words: cancer, sialic acid, siglec
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Introduction
Siglecs are sialic acid binding Ig-like lectins expressed mainly on
the surface of hemopoietic and immune cells (Crocker et al. 2007;
Crocker and Redelinghuys 2008). Siglec-15 is highly conserved across
vertebrate evolution (Angata et al. 2007; Angata 2020) and con-
sists of an N-terminal sialic acid-binding V-set domain, a C2-set
domain, a positively charged transmembrane region and a cytosolic
tail. Through its charged transmembrane region, Siglec-15 becomes
associated with the immunoreceptor tyrosine-based activation motif
(ITAM) adaptor proteins, DAP10 or DAP12, and has been shown
to trigger cell signaling following cross-linking at the cell surface
(Angata et al. 2007; Takamiya et al. 2013; Stuible et al. 2014).
Under steady-state conditions, it is primarily expressed on osteo-
clasts following stimulation of progenitors with RANKL and CSF-
1 (Hiruma et al. 2011; Ishida-Kitagawa et al. 2012; Stuible et al.
2014). Consistent with a functional role of Siglec-15 in bone resorp-
tion, Siglec-15-deficient mice exhibit a mild osteopetrotic phenotype
(Hiruma et al. 2013; Kameda et al. 2013) and monoclonal antibodies
to Siglec-15 can be used to treat osteoporosis (Sato et al. 2018).
Besides osteoclasts, Siglec-15 is expressed on a subset of tissue
macrophages (Angata et al. 2007) and is upregulated on tumor-
associated macrophages (TAMs) (Takamiya et al. 2013; Wang et al.
2019). In addition to TAMs, some tumor cells upregulate Siglec-15
expression where it contributes to the immunosuppressive microen-
vironment by blocking CD8 T cell proliferation (Wang et al. 2019).
Recent genome-wide association studies have shown that Siglec-15
can function as a susceptibility factor to infectious diseases, including
recurrent vulvovaginal candidiasis (Jaeger et al. 2019) and pulmonary
tuberculosis (Bhattacharyya et al. 2019).
The initial studies with recombinant Siglec-15 suggested that
the sialyl Tn (sTn) antigen (Neu5Acα2,6GalNAc) is a preferred
glycan ligand for mouse and human Siglec-15 (Angata et al. 2007).
STn is a truncated O-glycan that is overexpressed on mucins in
carcinomas such as breast, ovarian, lung and gastric cancers (Julien
et al. 2012; Munkley 2016). ST6GalNAc-I is a sTn synthase that
catalyzes α2,6-sialyl linkage to GalNAcα-O-Ser/Thr (Marcos et al.
2004; Julien et al. 2012). In normal cells, T synthase competes
with ST6GalNAc-I by adding Gal to GalNAc giving rise to core
1 or T antigen, and this activity of T synthase is dependent on a
chaperone known as Cosmc. In cancers, mutation of Cosmc results in
elevated sTn levels that are associated with poor prognosis and out-
come (Beatson et al. 2015; Munkley 2016). Interestingly, when lung
carcinoma cells overexpressing the sTn synthase were co-cultured
with THP-1 macrophage-like cells overexpressing Siglec-15, this
led to increased production of immunosuppressive TGF-β by the
THP-1 cells (Takamiya et al. 2013). Taken together, these observa-
tions suggest that interactions between sTn and Siglec-15 can play
important roles in crosstalk between tumor cells and the immune
system.
In the present study, we have further investigated the interac-
tion between Siglec-15 and sTn on tumor cells and its functional
consequences. Based on binding assays with lung and breast cancer
cell lines and glycan-modified cells, we did not observe evidence for
recognition of sTn by Siglec-15 in these cell models. However, using
a structurally diverse and sequence-defined glycan microarray, we
have shown that Siglec-15 exhibits higher avidity to sialylated glycans
other than sTn. In addition, we were unable to demonstrate enhanced
TGF-β secretion following Siglec-15 cross-linking in overexpressing
THP-1 cells, but we did observe activation of the SYK/MAPK signal-
ing pathway that may modulate their functional activity.
Results
Siglec-15 binds lung and breast cancer cell lines
We tested a panel of human nonsmall cell lung cancer and breast
carcinoma cell lines for binding of precomplexed human Siglec-15-
IgG1-Fc fusion protein. Siglec-15-Fc protein bound lung cancer cells
with varying avidities (Figure 1A and Supplementary Figure S1A).
All the breast carcinoma cell lines tested bound Siglec-15-Fc at a
similar level (Figure 1B and Supplementary Figure S1B). In all cases,
Siglec-15-Fc binding was sialic acid-dependent as pretreatment of the
cells with sialidase strongly reduced binding (Figure 1). Canonical
Siglec binding to glycan ligands requires a conserved Arg residue that
forms a salt bridge with the carboxylate of sialic acid (Crocker et al.
2007). The binding of Siglec-15-Fc to cancer cell lines was greatly
reduced on mutation of the key Arg143 to Ala (Figure 1A and B and
Supplementary Figure S1C and D). Unlike a previous study (Angata
et al. 2007), however, this mutation did not completely abrogate
Siglec-15 binding to cancer cell lines.
Siglec-15 binds ligands other than sialyl Tn on cancer
cell lines
STn was reported to be an important glycan ligand for Siglec-15
in binding assays using a set of PAA-biotin glycans and cell-based
studies (Angata et al. 2007, Takamiya et al. 2013). To investigate
whether sTn is expressed on the lung and breast cancer cell lines
that bound Siglec-15-Fc fusion protein, we performed flow cytometry
with a commercial antibody (clone 3F1) against sTn. The leukemic
cell line, K562, was used as a positive control, as it is known to
express endogenous sTn (Sewell et al. 2006). 3F1 stained K562 cells
in a concentration-dependent manner and this was strongly reduced
following treatment of cells with sialidase (Supplementary Figure S2).
Moreover, the binding was inhibited in the presence of sTn-PAA-
biotin glycoconjugate (data not shown). In striking contrast to K562
cells, we could not detect sTn expression using 3F1 on any of the
lung and breast cancer cell lines, including those that bound strongly
to Siglec-15-Fc (Figure 2 and Supplementary Figure S3).
To further investigate whether sTn can function as a cell surface
ligand for Siglec-15, we overexpressed sTn synthase, ST6GalNAc-
I, in the H460 lung cancer cell line. This cell line was selected
because it bound at low to intermediate levels to Siglec-15 and
should allow any increased binding to be readily evident. Over-
expression of ST6GalNAc-I led to a greater than 70-fold increase
in surface levels of sTn as detected by 3F1 antibody, which was
greatly reduced by sialidase pretreatment of the cells (Figure 3A
and Supplementary Figure S4A). High expression of sTn was also
associated with altered α2,3 sialylation, as evident from the reduced
MALII lectin binding (Figure 3B and Supplementary Figure S4B).
However, overexpression of sTn in H460 cells had no impact on
Siglec-15-Fc binding compared to the wild type cells (Figure 3C and
Supplementary Figure S4C). Moreover, the binding of Siglec-15-Fc to
K562 cells that express endogenous sTn was not affected by pretreat-
ment with the 3F1 anti-sTn monoclonal antibody expected to block
sTn-dependent binding (Figure 3D and Supplementary Figure S4D).
Therefore, in contrast to previous studies, our results suggest that sTn
does not function effectively as a cell surface ligand for Siglec-15.
Identification of glycan ligands for Siglec-15
To identify glycan ligands for Siglec-15 other than sTn, we
performed glycan array analyses of Fc-chimeras of human Siglec-
15 wildtype and Arg143Ala mutant and compared the results
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Fig. 1. Siglec-15-Fc binds lung and breast adenocarcinoma cell lines. For the binding assay, recombinant Siglec-15 human IgG1 Fc fusion protein (Siglec-15-
Fc) wildtype (1 μg/mL) or R143A mutant (1 μg/mL) was mixed with goat anti-human IgG Fc-FITC (1 μg/mL) to prepare immune-complexes. Lung and breast
carcinoma cell lines, pretreated with or without sialidase, were incubated with Siglec-15-Fc immune complexes. Negative controls were incubations with anti-
human IgG Fc-FITC without the addition of Siglec-15-Fc. The binding of Siglec-15-Fc to cancer cells was analyzed by flow cytometry. The results are mean ± SEM
of fluorescence intensities (MFI) measured from three independent experiments for each lung (A) and breast (B) cancer cell line, relative to the nonstained
control. ∗, P < 0.05; ∗∗, P < 0.01; ∗∗∗, P < 0.005; ns, not significant.
Fig. 2. Sialyl Tn is not expressed on lung and breast cancer cell lines that bind Siglec-15-Fc. Expression of sTn on lung (A) and breast (B) cancer cell lines was
detected by anti-sTn antibody (clone 3F1) (7.5 μg/mL) followed by APC conjugated anti-mouse IgG. An isotype matched mouse IgG was used as the negative
control. The results are plotted as median fluorescence intensities ± SEM from 3 independent experiments, relative to the signal with secondary antibody alone.
∗∗∗, P < 0.005; ∗∗∗∗, P < 0.001; ns, not significant.
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Fig. 3. Enhanced sialyl Tn expression does not lead to increased Siglec-15-Fc binding. (A) NCI-H460 wildtype cells and NCI-H460 cells over-expressing ST6GalNAc-
I were analyzed for sTn expression using mouse anti-sTn antibody (clone 3F1) followed by APC-conjugated anti-mouse IgG. Specificity of antibody binding was
analyzed using cells pretreated with sialidase to destroy the epitope. An isotype-matched mouse IgG was used as the negative control. (B) NCI-H460 wildtype
and ST6GalNAc-I-expressing cells were stained using biotinylated MAL-II lectin (5 μg/mL) followed by streptavidin-FITC. Staining with streptavidin-FITC alone
was used as the negative control. (C) H460 wildtype and ST6GalNAc-I-expressing cells, untreated or pretreated with sialidase, were incubated with Siglec-15-Fc
wildtype and R143A mutant precomplexed with anti-human IgG1 Fc-FITC (at ratio 1:1) and analyzed by flow cytometry. Negative controls were incubations with
human IgG1 precomplexed with anti-human IgG1 Fc-FITC (at ratio 1:1). (D) K562 cells, preincubated with or without anti-sTn antibody (20 μg/mL), were analyzed
for Siglec-15 binding as described in (C) above. Results are plotted as median fluorescence intensity (MFI) ± SEM for 3 independent experiments, relative to the
signal with secondary antibody alone. ∗∗∗∗, P < 0.001; ns, not significant.
with those using the sTn specific 3F1 antibody (Figure 4). We
used a newly constructed glycan microarray consisting of 82
sequence-defined neoglycolipid (NGL) probes. Sixty of these were
derived from synthetic amino-terminating glycans and naturally
derived glyco-amino acids (Supplementary Table SI). These were
conjugated to a newly synthesized aldehyde-functionalized phospho-
lipid reagent N-(4-formylbenzamide)-1,2-dihexadecyl-sn-glycero-3-
phosphoethanolamine, abbreviated to DA (W Chai and colleagues,
submitted); they are designated DA-NGLs (Supplementary Table SII).
As controls, 22 conventional NGLs and glycolipids were included.
Binding of Siglec-15-Fc was observed to the sTn, α2,6-sialyl
GalNAc-antigen linked to Ser or Thr (DA-NGL probes 28 and 29,
Figure 4 and Supplementary Table SII). There was binding also to
aminooxy AO-NGLs derived from the N-glycolyl and N-acetyl forms
of the reducing disaccharide obtained from bovine submaxillary
mucin (Chai et al. 1992) (probes 74 and 75); and to the α2,3-sialyl
and α2,3/α2,6-disialyl core 1 linked to Ser or Thr (DA-NGL probes
33, 36 and 37) and to the AO-NGL analogue (probe 78). Siglec-15-
Fc binding could also be detected to α2,3- and α2,6-sialyl lactose
(probes 5, 6 and 63). However, the predominant binding was detected
to α2,6-sialyl glycans with lacto-N-tetraose and lacto-N-hexaose
backbone sequences. These included the α2,6- monosialyl LSTb and
the α2,3/α2,6-disialyl DSLNT and DSMFLNH (probes 8–10 and
66, Figure 4 and Supplementary Table SII). With the Arg143 to Ala
mutant the binding was markedly reduced, but not abolished. In sum,
Siglec-15 binding contrasts with the binding observed with the 3F1-
IgG antibody, which is restricted to the α2,6-sialylated GalNAc, sTn
antigen. These results are consistent with the cell-based studies above.
Cross-linking Siglec-15 on monocytic cells did not
enhance TGF-β secretion
Previously it was shown that co-culture of sTn-expressing lung cancer
cells with either M-CSF-induced human macrophages or Siglec-15-
transfected THP-1 monocyte-like cells promoted secretion of TGF-
β (Takamiya et al. 2013). We performed similar experiments using
THP-1 and U937 monocyte-like cells stably expressing human Siglec-
15 (Supplementary Figure S5) co-cultured with lung and breast can-
cer cells. However, we failed to see any evidence for Siglec-15-
dependent increase in TGF-β production under the conditions used
(Figure 5A–C).
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Fig. 4. Glycan microarray analysis of human Siglec-15-Fc chimeras and anti-sTn 3F1 mAb. The Siglec-15-Fc chimeras were analyzed as precomplexes with
biotinylated anti-human IgG antibody at 1:1 ratio (by weight) and at a final concentration of 2 μg/mL. The anti-sTn 3F1-IgG was analyzed at 50 μg/mL.
The results are the means of fluorescence intensities of duplicate glycan probe spots, printed at 5 fmol/spot. The probes are grouped according to their
backbone-type sequences: disaccharide-based, lactose (Lac) and lactosamine (LN); tetrasaccharide- or hexasaccharide-based, lacto-N-tetraose (LNT), lacto-N-
neo-tetraose (LNnT), lacto-N-hexaose (LNH); poly-N-acetyllactosamine (PolyLN); N-glycans; glycolipid; O-glycan; glycosaminoglycans (GAGs); Glc and GlcNAc
homo-oligomers; monosaccharides. The probe sequences are listed in Supplementary Table SI.
To determine whether cross-linking Siglec-15 on monocytic cells
with antibodies enhanced TGF-β levels, THP-1 mock- and Siglec-
15-transfected cells were incubated with two monoclonal antibodies
against Siglec-15, 25E9 and A9E8, followed by cross-linking with
a secondary antibody. Consistent with the co-culture studies, cross-
linking Siglec-15 on THP-1 cells did not increase TGF-β secre-
tion compared to the isotype control antibody (Figure 5D). These
results suggest that Siglec-15-induced SYK signaling does not enhance
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Fig. 5. Effect of cross-linking Siglec-15 on TGF-β secretion in monocytic cells. (A) Lung cancer cell lines T47D and HCC827 that show differential expression
of Siglec-15 ligands were co-cultured with THP-1 mock and human Siglec-15-expressing monocytic cells for 24 h in serum free medium. (B) T47D cells were
co-cultured with U937 mock and human Siglec-15-expressing cells. (C) H460 wildtype and sTn-expressing (ST6GalNAc-I) cells were co-cultured with THP-1 mock
and Siglec-15-expressing cells. (D) Mock-transfected and Siglec-15-expressing THP-1 cells were incubated with monoclonal antibodies against human Siglec-15
and crosslinked with anti-mouse IgG F(ab’)2 secondary antibody. The cells were cultured in macrophage serum-free medium for 24 h. To determine secretion
of TGF-β, supernatants were concentrated as described in the Materials and Methods, acidified to release active TGF-β, neutralized and analyzed using Human
TGF-β1 Quantikine ELISA kit according to the manufacturer’s instructions. The results are mean concentrations ± SD for two independent experiments.
TGF-β secretion. SYK signaling, however, triggers activation of other
kinases including ERK1/2 and p38 MAPK, implicated in regulat-
ing inflammation in macrophages (Xiao et al. 2002). Therefore,
we explored whether cross-linking Siglec-15 triggered activation of
ERK and p38 MAPK in THP-1 cells expressing Siglec-15. Cross-
linking Siglec-15 on THP-1 cells expressing Siglec-15 with anti-
Siglec-15 whole mouse IgG1 antibodies stimulated phosphorylation
of ERK1/2 (at T202/Y204) unlike the isotype control antibody,
while this was inhibited when cells were pretreated with the spe-
cific MEK1/2 inhibitor PD184352 or the SYK inhibitor BI1002494
(Figure 6A and Supplementary Figure S6). Moreover, the anti-Siglec-
15 human IgG KO antibody (L234A/L235A mutant), 25E09, which
no longer binds Fcγ receptors also enhanced ERK phosphoryla-
tion (Figure 6B and Supplementary Figure S7) indicating that ERK
activation induced by the antibodies is independent of Fc receptor
engagement. These results suggest that ERK is activated downstream
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of Siglec-15/SYK signaling. In contrast to ERK activation, we failed to
see increased phosphorylation of p38 MAPK following cross-linking
of Siglec-15 in THP-1 cells (Supplementary Figure S8).
Discussion
Siglec-15 is considered to be evolutionarily one of the most ancient
Siglecs and has been mainly studied for its role in osteoclast dif-
ferentiation and as a potential therapeutic target in osteoporosis
(Ishida-Kitagawa et al. 2012; Hiruma et al. 2013; Stuible et al. 2014;
Sato et al. 2018). Recent studies have also highlighted an important
role of Siglec-15 in modulating the tumor microenvironment and
favoring tumor suppression (Takamiya et al. 2013; Wang et al.
2019). This has been proposed to occur in 2 ways, either by sTn-
dependent modulation of TGF-β production by Siglec-15-expressing
macrophages (Takamiya et al. 2013), or by suppressing cytotoxic
CD8 T cell proliferation via interactions with Siglec-15 expressed
on macrophages or tumor cells (Wang et al. 2019). In this study,
we have revisited the interplay between sTn and Siglec-15 in cancer
immunosuppression and identified several sialylated glycan ligands
of Siglec-15 other than sTn. Siglec-15-Fc multimers bound sialylated
ligands on most lung and breast carcinoma cells with differential
avidity. Mutation of the conserved “essential arginine” Arg143 that
is critical for interaction with sialic acid to alanine and sialidase
pretreatment of cancer cells resulted in significant reduction of Siglec-
15 binding. Surprisingly, however, sTn expression was not detected
on cancer cell lines that bound Siglec-15 and sTn overexpression
in a lung cancer cell line expressing ST6GalNAc-I enzyme did not
increase Siglec-15-Fc binding. Moreover, monocytic THP-1 cells over-
expressing human Siglec-15 did not bind sTn-PAA-biotin sugar (data
not shown). Together, these results suggest that there is a disconnect
between sTn expression and Siglec-15 binding which is in contrast to
previous findings (Takamiya et al. 2013).
The results of the glycan array showed clearly that Siglec-15 can
bind sTn antigen and are therefore consistent with the ELISA studies
reported by Angata et al. (Angata et al. 2007). A previous report
showed that Siglec-15 could recognize both α2,6- and α2,3-linked
sialic acid in the context of synthetic high affinity sialic acid analogues
(Briard et al. 2018) and this is consistent with our glycan array data
using natural sialosides. A new finding here is that Siglec-15 showed
higher avidity binding to sialylated glycan structures, DSMFLNH
(disialyl monofucosyllacto-N-hexaose), LSTb (sialyllacto-N-tetraose
b) and DSLNT (disialyllacto-N-tetraose) which contain sialic acid
α2,6-linked to an internal GlcNAc. A similar preference for this
motif, as present in the milk sugar LSTb, was noted for Siglec-7
(Yamaji et al. 2002). We propose that the Siglec-15 ligands expressed
on the lung and breast cancer cell lines may have structural features
similar those of the glycans identified by our microarray analyses. It
was shown previously that ST6GalNAcVI is the enzyme required for
α2,6-sialylation of GlcNAc in disialyl Lewis a and is upregulated in
colon cancer cell lines (Tsuchida et al. 2003). It will be interesting in
the future to investigate the role of this enzyme in generation of Siglec-
15 ligands on cancer cells. A comprehensive glycomics approach
could be used to identify the potential sialoglycan ligands of Siglec-15
in these cancer cell lines (Chik et al. 2014). Another approach is to
identify glycoprotein counter-receptors on cancer cells for Siglec-15
(Chang et al. 2017) and characterize their glycan ligands.
Cross-linking Siglec-15 with sialylated ligands activates ITAM
signaling via DAP12 which is mediated by recruitment and activation
of SYK tyrosine kinase (Ishida-Kitagawa et al. 2012; Angata 2020).
Cross-linking macrophage-expressed Siglec-15 by sTn on cancer cells
has been shown to enhance TGF-β secretion (Takamiya et al. 2013).
This is at odds with the findings presented here, where there was
no increase in TGF-β secretion upon co-culturing cancer cell lines
(with and without sTn expression) with Siglec-15 over-expressing
THP-1 monocytic cells. In co-culture models, the observed effects
could result from engagement of multiple receptors on the surface of
immune cells. This was the rationale for our testing the effect of cross-
linking Siglec-15 using monoclonal antibodies as surrogate ligands.
Cross-linking Siglec-15 on THP-1 cells with antibodies, however,
did not enhance TGF-β secretion. SYK signaling is mediated by
various intermediary kinases such as AKT, JNK (Yi et al. 2014), ERK
(Eliopoulos et al. 2006, Parsa et al. 2008), p38 MAPK (Zhang et al.
2009) and PKC (Takada and Aggarwal 2004). We demonstrated by
flow cytometry that cross-linking Siglec-15 on THP-1 cells triggers
phosphorylation of ERK, but not p38 MAPK. Further studies are
required to understand the downstream effects of Siglec-15/SYK/ERK
signaling cascade.
Overall, our findings suggest that sTn, a proposed ligand of
Siglec-15, is not detectably expressed on the cancer cell lines tested
and that forced sTn expression does not lead to an increase in Siglec-
15 binding at the cell surface. However, using structurally diverse
glycan arrays, we have identified several sialylated structures that
are well recognized by Siglec-15, some of which may be structurally
similar to natural ligands for Siglec-15 expressed on cancer cells.
From the present study it seems likely that sialylated ligands other
than sTn play important roles in the signaling functions of Siglec-15,
for example in osteoclast activation and suppression of CD8 T cell
proliferation.
Materials and methods
Materials
Human Siglec-15 wildtype and R134A mutant were expressed
as Fc fusion proteins by cloning the cDNAs of the extracellular
domains fused to human IgG1 Fc region into pcDNA3 and transient
transfection of CHO cells. Monoclonal antibodies against human
Siglec-15, 25E9 (WO2011041894, Alethia Biotherapeutics) and
A9E8 (WO2013034660, MedImmune) were produced by transient
co-transfection of HEK293 cells with pIRES-DHFR containing the
heavy chain cDNA (either murine IgG1 (25E9, A9E8) or huIgG1KO
with Fc modifications to silence effector function (25E09; LALA
mutant)) and pcDNA3 containing the light chain cDNA. Antibodies
and Fc fusion proteins were purified by affinity chromatography on
protein A/G beads. The SYK inhibitor BI1002494 (Lamb et al. 2016)
was from Boehringer Ingelheim (www.opnme.com) and the MAPK
inhibitor PD184352 was from the Division of Signal Transduction
and Therapy (DSTT), University of Dundee. FetalClone II serum
and human Fc block were from ThermoFisher Scientific. Sialidase
from Vibrio cholerae and FITC-conjugated goat anti-human IgG
Fc were from Sigma (Dorset, UK). Biotinylated MAL II was from
Vector Laboratories (Peterborough, UK). Human and mouse isotype
controls were from Abcam (Cambridge, UK). Anti-mouse and anti-
human IgG F(ab’)2 antibodies were from Stratech (UK). Anti-sialyl
Tn antibody (HB-sTn clone 3F1) was from SBH Sciences (USA).
FITC conjugated Streptavidin and PE- and APC-conjugated anti-
mouse IgG were from Biolegend (London, UK).
Cell culture
All cell lines were from American Tissue Culture Collection
(ATCC). HCC44, HCC827, NCI-H460, NCI-H292, NCI-H2405,
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Fig. 6. Effect of cross-linking Siglec-15 on ERK activation. (A) Mock-transfected THP-1 and Siglec-15-expressing cells were incubated with mouse IgG antibodies
(clones 25E9 and A9E8) against human Siglec-15 or crosslinked using anti-mouse IgG F(ab’)2 secondary antibody. Negative controls were incubations with
the isotype-matched IgG followed by anti-mouse IgG F(ab’)2. (B) Mock-transfected THP-1 and Siglec-15-expressing cells were incubated with human IgG1 KO
monoclonal antibody (clone 25E09) against human Siglec-15 or crosslinked using anti-human IgG F(ab’)2 secondary antibody. Negative controls were incubations
with isotype-matched human IgG1 followed by anti-human IgG F(ab’)2. For ERK and SYK inhibition, cells were pretreated with PD184352 (2 μg/mL) and BI1002494
(10 μg/mL) for 1 h before cross-linking Siglec-15 with antibodies. Cells were fixed with paraformaldehyde, permeabilized and stained for pERK1/2 (T202/Y204)
antibody (1:50 dilution). Results are plotted as median fluorescence intensities ± SEM from 3 independent experiments, normalized to the untreated control. ∗,
P < 0.05; ∗∗, P < 0.01; ∗∗∗, P < 0.005; ∗∗∗∗, P < 0.001; ns, not significant.
MDA-MB-231, T47D, BT549, U937 and THP-1 were cultured
in RPMI GlutaMAX medium supplemented with 10% (v/v) fetal
bovine serum (FBS) and 1% penicillin/streptomycin. CAL120
and A549 were cultured in DMEM medium supplemented with
10% (v/v) fetal bovine serum (FBS), 2 mM L-glutamine and 1%
penicillin/streptomycin. Lung cancer cell line SKMES1 was cultured
in EMEM containing 10% (v/v) fetal bovine serum (FBS), 2 mM
L-glutamine and 1% penicillin/streptomycin.
Sialidase treatment of cells
Adherent cells were harvested using PBS containing 1 mM EDTA.
Cells were washed twice and resuspended in RPMI medium
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containing 0.1 mU/mL of V. cholerae sialidase for 1 h at 37◦C,
followed by washing twice with PBS containing 1% FetalClone II
serum.
Generation of stable cell lines expressing Siglec-15 and
ST6GalNAc-I
Human Siglec-15 lentiviral construct was generated by inserting
human full-length Siglec-15 cDNA into pCDH-EF1-MCS-(PGK-
GFP-T2A-Puro) vector. For generating the lentiviral particles,
293TN Producer Cells (System Biosciences, www.systembio.com)
were cotransfected with the lentiviral expression vector and the
pPACKH1 Lentiviral Packaging Plasmid Mix (System Biosciences)
according to the manufacturer’s protocol. The lentiviral particles
were harvested and concentrated 10-fold using PEG-itTM Virus
Precipitation Solution as described by System Biosciences.
Human monocytic cell lines THP-1 and U937 (1 × 106) were
infected with 100 μL of lentiviral particles per well and 5 μg/mL
polybrene by spinoculation. 48 h posttransfection, cells were selected
with 2 μg/mL puromycin for 10 days. Puromycin resistant clones
were then expanded and analyzed for GFP and Siglec-15 expression.
H460 cells overexpressing sTn were generated by inserting the cDNA
coding for full length ST6GalNAc-I into pIRES-puro via EcoRV and
BamHI and expanding puromycin-resistant clones after transfection
using lipofectamine.
Flow cytometry analyses
Siglec-15-Fc Multimer Staining. Immune complexes were prepared
by mixing 1 μg/mL of Siglec-15-Fc wildtype or R143A mutant and
1 μg/mL of FITC-conjugated goat anti-human IgG Fc in 100 μL
phosphate-buffered saline (PBS) containing 1% FetalClone II serum
(FACS buffer), for 1 h on ice. 1 × 106 cancer cells were suspended
in the Siglec-15-Fc immune complexes and after incubation on ice
for 30 min, the nonbound immune-complexes were washed off by
centrifugation and cell pellets resuspended in 500 μL of FACS buffer.
Human IgG1 was used as a negative control.
Sialyl Tn Antibody Staining. For sTn staining, 1 × 106 cells were
incubated with human Fc block (2.5 μL) in 100 μL of FACS buffer
for 10 min at room temperature. Cells were stained with varying con-
centrations of mouse monoclonal antibody against sTn (3.3 μg/mL,
10 μg/mL and 30 μg/mL). Unbound antibodies were washed off
by centrifugation, and cell pellets were resuspended in PE or APC-
conjugated anti-mouse IgG antibody in 100 μL of FACS buffer and
incubated for 30 min on ice. Cells were centrifuged and resuspended
in 500 μL of FACS buffer. Mouse isotype control was used as the
negative control.
Intracellular Phosphoprotein Staining. THP-1 mock-transfected and
Siglec-15-expressing cells were incubated with anti-human Siglec-15
antibodies (whole mouse IgG1 and human IgG1 KO) for 1 h on ice
and crosslinked with anti-mouse/human IgG F(ab’)2 for 30 min at
37◦C. Mouse/human IgG1 antibodies were used as negative controls.
For inhibition experiments, THP-1 cells were pretreated with 2 μM
PD184352 or 10 μM BI1002494 for 1 h at 37◦C before cross-
linking with anti-Siglec-15 antibodies. The cells were fixed by adding
ice-cold 4% (v/v) paraformaldehyde and incubating for 15 min at
room temperature. The cells were washed with cold FACS buffer
and permeabilized with ice-cold 90% methanol/distilled water, added
slowly while vortexing to prevent cell clumping, for 30 min on ice.
The cells were washed twice with excess FACS buffer to remove
the methanol before incubating first with 1:50 Fc block in FACS
buffer and then with phospho-protein antibodies (1:50 p-ERK1/2
T202/Y204 or 1:50 p-p38 MAPK T180/Y182 antibodies from Cell
Signaling Technologies) in FACS buffer for 1 h at room temperature.
The cells were washed twice with excess FACS buffer and incubated
with anti-rabbit IgG F(ab’)2-AF647 conjugate detection antibody
(1:1000) in FACS buffer for 30 min at room temperature in the dark.
The cells were washed twice with FACS buffer, resuspended in FACS
buffer, and acquired on a BD FACSCantoTM II. All flow cytometry
data were analyzed using FlowJo software.
Determination of TGF-β levels by ELISA
Cancer cell lines were grown in 6-well plates until confluent and
fixed using 2% paraformaldehyde for 10 min at room temperature.
Cells were washed with PBS and monocytic cells (THP-1/U937)
expressing human Siglec-15 (2 × 106 per well) in macrophage
serum free medium were added. After 24 h, culture supernatants
were centrifuged to remove cell debris and concentrated 10 times
using centrifugal concentrators (10 K MWCO). The concentrated
culture supernatants were analyzed for TGF-β levels using Human
TGF-β1 Quantikine ELISA kit (R&D Systems) and following the
manufacturer’s instructions.
Glycan array analysis
Glycan microarray analysis was carried out using a newly
constructed glycan microarray comprised of 82 sequence-defined
NGL probes. Sixty NGLs were prepared from synthetic amino-
terminating glycans and naturally-derived serine or threonine glyco-
amino acids (Supplementary Table SI; MIRAGE document). To
prepare the NGLs, the amino-terminating glycans were conjugated
to a the newly synthesized aldehyde-functionalized phospho-
lipid reagent N-(4-formylbenzamide)-1,2-dihexadecyl-sn-glycero-
3-phosphoethanolamine, abbreviated as DA; they are designated
DA-NGLs (Supplementary Table SII; details of preparation of DA-
NGLs and validation of the microarrays are described elsewhere by
W Chai and colleagues, submitted). As controls, 22 conventional
NGLs and glycolipids were included. The microarrays were prepared
via noncovalent immobilization on nitrocellulose-coated glass slides
and analyzed with the proteins following established procedures (Liu
et al. 2012) (Supplementary Table SI; MIRAGE document).
Graphs and statistics
All of the graphs (mean ± SEM) were plotted, and statistical analyses
were performed using GraphPad Prism 6.07 software. Multiple com-
parisons of data were performed using ANOVA followed by Tukey’s
post hoc HSD test for pairwise comparison.
Supplementary data
Supplementary data are available at Glycobiology online.
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